Two Sigma Advisers’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Two Sigma Advisers’s Portfolio CYT Stock Details CYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,900	Closed	-$67.3K	–	2628
2023 Q2	$67.3K	Sell	25,900 -100	-0.4%	-$209	﹤0.01%	2244
2023 Q1	$47.3K	Hold	26,000	–	–	﹤0.01%	2453
2022 Q4	$42.9K	Sell	26,000 -2,300	-8%	-$3.69K	﹤0.01%	2374
2022 Q3	$54K	Buy	28,300 +5,900	+26%	+$15.4K	﹤0.01%	2368
2022 Q2	$67K	Buy	+22,400	New	+$57.2K	﹤0.01%	2445

Other funds holding CYT

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

OMC

OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

VAS

VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

Two Sigma Advisers's CYT Position: Q3 2023 in Review

Two Sigma Advisers sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2023, closing a stake of 25,900 shares — an estimated $67.3K sold.

Two Sigma Advisers first reported a position in CYT in Q2 2022 and held it in 5 quarters. The position peaked at $67.3K in Q2 2023. 41 funds tracked by Wall St. Rank hold CYT as of Q3 2023.

Two Sigma Advisers reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Two Sigma Advisers sold 25,900 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $67.3K.
Two Sigma Advisers first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
Two Sigma Advisers's Cyteir Therapeutics, Inc. Common Stock position peaked at $67.3K in Q2 2023.
41 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.